Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics

Published: Saturday, June 28, 2014
Last Updated: Saturday, June 28, 2014
Bookmark and Share
Big data approach bridges the gap between genomics and personalized medicine.

Definiens AG which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment said that it has closed a round of financing for € 15 Million. The round was led by Wellington Partners, a leading pan-European venture capital firm.

Gilde Healthcare co-led the financing round and was joined by the other existing investors Cipio Partners and TVM Capital in the financing. In conjunction with the financing, Dr. Rainer Strohmenger, General Partner and Managing Director for Wellington, will join Definiens' Board of Directors.

The new funds will allow Definiens to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics. Major investments will be made in executing the company’s Tissue Phenomics strategy, enabling partnerships with leading medical centers and pharmaceutical companies to advance the diagnosis and treatment of cancer.

Tissue Phenomics is based on Definiens' proprietary Cognition Network Technology®, invented by Nobel laureate and founder Prof. Gerd Binnig and involves a unique big data approach to develop new tissue-based diagnostic tests for oncology and immunotherapy.

Using these new diagnostic tests will allow for better prediction of patient outcomes and identification of drug responders, thereby bridging the gap between genomic data and cancer outcomes.

Dr. Rainer Strohmenger, General Partner and Managing Director at Wellington Partners, commented: “We have been following Definiens for many years and have always been impressed by the visionary concept and exciting technology the company has. We believe that Definiens now is approaching an inflection point which will have a significant impact on the growth potential and strategic value of this business for the leading players in imaging, diagnostics and oncology drug development.”

Thomas Heydler, CEO at Definiens, stated: “Wellington Partners is one of the few investors experienced in both diagnostics and healthcare IT with a strong track record of successfully building and capturing value from businesses in these areas. We are honored to add Wellington to our investor base and welcome Dr. Strohmenger to our Board of Directors. This financing will allow us to pursue our aggressive growth strategy to further expand our global leadership in Tissue Phenomics.”

Dr. Gerald Möller, Chairman at Definiens AG, added: “The use of state-of-the-art information technology in medicine will dramatically improve the way patients will be diagnosed and treated and the way new drugs and diagnostic tests will be developed. This change will not only lead to improved patient outcomes but also drive personalized medicine forward, and I am convinced that Definiens will play an important role in accelerating this change, especially in the fields of pathology, cancer, and immunotherapy. The fact that we have attracted this significant financing with new lead investor Wellington is another confirmation of Definiens’ strong position.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Thursday, November 15, 2012
Definiens Closes €10 Million Round to Grow its Clinical Digital Pathology Business
The financing was led by new investor Gilde Healthcare Partners, a transatlantic investment firm with €450 million under management, focusing on the private healthcare sector.
Tuesday, October 02, 2012
Definiens Strengthens Leadership with Key Appointment
Former Aperio executive and digital pathology market expert, Dr. Martin Stuart, joins executive team.
Thursday, February 02, 2012
Definiens Digital Pathology Software Utilized for Hamner Institutes Liver Toxicology Study
Definiens TissueStudio™ and Definiens developer XD help quantify changes in apoptosis in the liver following chemical exposure.
Monday, June 07, 2010
Definiens Image Analysis Technology Improves Accuracy in Scoring Her2/neu in Breast Cancer Biopsies
New multi-dimensional image analysis platform aids diagnosis and treatment of breast cancer.
Wednesday, June 03, 2009
Definiens and Bioscan Team Up for Cooperative Marketing Efforts
Under the terms of the agreement, the companies will offer integrated solutions for intelligent small animal imaging analysis.
Wednesday, December 03, 2008
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!